Abstract:What's new? Although some countries have reached key performance indicators toward the elimination of cervical cancer and its causative agent, human papillomavirus, most are yet to reach the vaccination and screening targets. The scientific basis for strategies to accelerate the elimination of cervical cancer was recently reviewed at a dedicated 2023 EUropean Research Organization on Genital Infection and Neoplasia (EUROGIN) workshop. The reviewed evidence suggests that strategies with more ambitious use of human papillomavirus vaccines (gender‐neutral vaccination or concomitant vaccination and screening) would accelerate elimination of human papillomavirus and cervical cancer. At the 2023 EUROGIN workshop scientific basis for strategies to accelerate the elimination of cervical cancer and its causative agent, human papillomavirus (HPV) were reviewed. Although some countries have reached key performance indicators toward elimination (>90% of girls HPV vaccinated and >70% of women HPV screened), most are yet to reach these targets, implying a need for improved strategies. Gender‐neutral vaccination, even with moderate vaccination coverage was highlighted as a strategy to achieve elimination more rapidly. It is more resilient against major disturbances in vaccination delivery, such as what happened during the coronavirus pandemic. Further, an analysis of ethical/legal issues indicated that female‐restricted vaccination is problematic. Extended catch‐up of vaccination with concomitant screening, and outreach to vulnerable groups were highlighted. Although birth cohorts with high coverage of HPV vaccination at school are protected against HPV, and HPVs have a very low reproductive rate in women above age 35, adult women below age 30 have inadequate direct protection. In addition to herd protection from gender‐neutral vaccination, this group can be protected by offering concomitant catch‐up HPV vaccination and HPV screening. Furthermore, hepatitis B vaccination experiences indicate that elimination cannot be achieved without prioritizing vulnerable/migrant populations. The long‐lasting durability of vaccination‐induced antibody responses suggests prolonged protection with HPV vaccines when adequately administrated. Finally, cost‐effectiveness modelling suggests that high‐coverage HPV vaccination in multiple population segments will be resource‐saving due to reduced need for screening. In summary, the workshop found that strategically optimal deployment of vaccination will accelerate elimination of HPV and cervical cancer.

Analysis of Implementation Strategies for Nationwide HPV Vaccination Programs Across European Union Countries

Cervical Cancer Screening Programs in Europe: The Transition Towards HPV Vaccination and Population-Based HPV Testing

Primary prevention of HPV-related diseases from the patients' perspective in Poland

A systematic literature review of human papillomavirus vaccination strategies in delivery systems within national and regional immunization programs

Cost-effectiveness of nonavalent vs bivalent HPV vaccine in Polish setting

Inventory of projects promoting HPV vaccination coverage in Germany

Estimating the time required to reach HPV vaccination targets across Europe

Estimate of global human papillomavirus vaccination coverage: analysis of country-level indicators

OP151 Cost-Utility Of Gender-Neutral HPV Vaccination In Ireland

Healthcare Professionals' Perspectives on HPV Recommendations: Themes of Interest to Different Population Groups and Strategies for Approaching Them

Scientific approaches toward improving cervical cancer elimination strategies

Key decision-making factors for human papillomavirus (HPV) vaccine program introduction in low-and-middle-income-countries: Global and national stakeholder perspectives

A comprehensive narrative review of challenges and facilitators in the implementation of various HPV vaccination program worldwide

Vaccine Hesitancy among European Parents—Psychological and Social Factors Influencing the Decision to Vaccinate against HPV: A Systematic Review and Meta-Analysis

Gender neutral HPV vaccination programs: Reconsidering policies to expand cancer prevention globally

A guide to global access to HPV vaccination to all women in low- and middle-income countries; a minireview of innovation and equity

Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands

Costs of introducing and delivering HPV vaccines in low and lower middle income countries: inputs for GAVI policy on introduction grant support to countries

Systematic review of cost-effectiveness studies on cervical cancer screening across Europe

A Systematic Review of Human Papillomavirus Vaccination Challenges and Strategies to Enhance Uptake

Barriers to and Facilitators for Accessing HPV Vaccination in Migrant and Refugee Populations: A Systematic Review